Jaguar health, inc. (JAGX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Revenue
Product revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

28

50

24

38

55

77

63

62

Total revenue

869

1,506

972

1,705

1,590

1,595

1,132

883

804

1,542

1,100

896

822

-

50

24

-

-

-

-

-

Operating expenses
Cost of product revenue

676

742

947

1,260

865

956

736

608

464

633

206

24

16

15

9

8

18

35

36

16

34

Research and development

1,582

1,393

1,307

1,697

1,421

1,310

1,481

1,604

757

1,235

851

926

1,255

1,534

1,967

1,953

1,751

2,061

1,239

1,751

1,423

Sales and marketing

1,469

1,499

1,698

2,173

1,565

2,712

2,716

2,690

1,712

2,139

663

157

122

130

136

54

164

245

165

163

190

General and administrative

3,149

3,685

3,106

3,196

3,514

3,515

2,703

3,059

2,998

2,735

3,070

2,137

3,303

1,663

1,115

1,416

1,788

1,555

1,390

1,300

1,093

Series B convertible preferred stock inducement expense

1,647

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Settlement of Tempesta Royalty License Agreement

-

-

640

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of goodwill

-

-

-

-

-

-

-

-

-

-

3,648

-

-

-

-

-

-

-

-

-

-

Impairment of indefinite-lived intangible assets

-

-

0

4,000

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

8,523

7,330

7,699

12,327

7,365

-

7,638

7,962

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

-

-

-

-

-

-

-

-

5,932

22,223

8,440

3,246

4,698

3,342

3,229

3,432

3,722

3,898

2,832

3,231

2,741

Loss from operations

-7,654

-5,823

-6,727

-10,622

-5,775

-12,110

-6,506

-7,079

-5,128

-20,681

-7,340

-2,350

-3,875

-3,314

-3,178

-3,408

-3,684

-3,842

-2,754

-3,168

-2,678

Interest expense

199

173

1,352

3,656

547

442

872

711

602

408

464

156

180

211

235

254

284

284

163

1,936

933

Other income (expense)

-82

31

28

14

6

-6

9

15

297

101

-14

0

1

0

-1

5

-15

-3

-42

15

3

Change in fair value of financial instruments

1

-6

-841

-207

46

-450

-26

-118

263

-59

-388

-700

453

-

-

-

-

-

-

-

-

Gain on Valeant settlement

-

-

-

-

-

-

1,204

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

173

328

Loss on extinguishment of debt

-

0

-335

-2,663

-1,942

-

-

-

-

-269

0

0

-207

-

-

-

-

-

-

-

-

Loss before income tax expense

-7,936

-

-7,545

-

-8,304

-

-6,138

-

-

-

-7,430

-

-

-

-3,415

-

-

-

-

-

-

Income tax expense

-

-

10

-

-

-

-

-

-

-

-12,190

-

-

-

-

-

-

-

-

-

-

Net loss

-7,936

-5,959

-7,555

-16,721

-8,304

-12,653

-6,138

-7,657

-5,696

-20,207

4,759

-1,805

-4,715

-3,676

-3,415

-3,657

-3,984

-4,130

-2,960

-5,262

-3,937

Deemed dividend

-

-

-

-

-

-

-

-995

995

-

-

-

-

-

-

-

-

0

0

159

187

Net loss attributable to common shareholders

-8,416

-8,018

-11,682

-16,721

-8,304

-10,663

-6,138

-8,652

-6,691

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) attributable to common shareholders

-

-

-

-

-

-

-

-

-

-

4,759

-1,805

-4,715

-

-

-

-3,984

-4,130

-2,960

-5,421

-4,124

Net income (loss) per share, basic

-

-

-

-

-

-

-

-

-

-

1.29

-

-

-

-0.30

-

-

-

-

-

-

Net income (loss) per share, diluted

-

-

-

-

-

-

-

-

-

-

1.11

-

-

-

-0.30

-

-

-

-

-

-

Basic:

-

-

-

-

-

-

-

-

-

-

3,695

-

-

-

11,264

-

-

-

-

-

-

Diluted:

-

-

-

-

-

-

-

-

-

-

4,480

-

-

-

11,264

-

-

-

-

-

-

Net loss per share, basic and diluted (in dollars per share)

-0.56

24.94

-2.00

-15.11

-16.84

-61.51

-37.77

-53.24

-0.75

-

-

-1.84

-0.33

-

-

-0.35

-0.43

0.09

-0.36

-1.00

-1.43

Weighted-average common shares outstanding, basic and diluted (in shares)

15,141

12,419

5,841

1,106

493

-8,117

162

162

8,631

-

-

979

14,157

-

-

10,314

9,307

8,204

8,123

5,410

2,874

Product revenue, net
Total revenue

869

1,506

972

1,705

1,590

1,595

1,132

883

626

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue
Total revenue

-

-

-

-

-

0

0

0

177

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of Series A convertible preferred
Deemed dividend

480

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series B convertible preferred stock
Deemed dividend

-

-

3,875

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series 1 warrants
Deemed dividend

-

-

252

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-